Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MK-7684A ± docetaxel vs docetaxel in metastatic NSCLC after platinum chemotherapy and immunotherapy
2022-501252-28-00Phase 2Completed
- Sponsor
- Merck & Co.
- Start
- Apr 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 20
01
Overview
Phase 2, randomised, double-blind trial of vibostolimab + pembrolizumab in non-small cell lung cancer (NSCLC) (3 arms), sponsored by Merck & Co. Primary endpoint: Progression-Free Survival (PFS) per RECIST 1.1 by BICR. Started Apr 2021; status: completed.
02
Drugs
vibostolimab + pembrolizumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2022-501252-28-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-501252-28-00.